|330.00||-3.11||-0.93%||Vol 81.18K||1Y Perf 111.07%|
|Apr 13th, 2021 14:40 DELAYED|
|- -%||- -|
|Target Price||378.00||Analyst Rating||Moderate Buy 2.19|
|Potential %||14.61||Finscreener Ranking||★★★ 49.46|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.54|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 75.83|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||14.93B||Earnings Rating||Sell|
|Price Range Ratio 52W %||75.12||Earnings Date||29th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|10 Years||1 997.67%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Apr 2021|
|Estimated EPS Next Report||1.10|
|EPS Growth Next 5 Years %||16.00|
|Avg. Weekly Volume||162.56K|
|Avg. Monthly Volume||267.53K|
|Avg. Quarterly Volume||324.80K|
ABIOMED Inc. (NASDAQ: ABMD) stock closed at 333.11 per share at the end of the most recent trading day (a -0.21% change compared to the prior day closing price) with a volume of 169.12K shares and market capitalization of 14.93B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1536 people. ABIOMED Inc. CEO is Michael R. Minogue.
The one-year performance of ABIOMED Inc. stock is 111.07%, while year-to-date (YTD) performance is 2.75%. ABMD stock has a five-year performance of 237.94%. Its 52-week range is between 156.67 and 387.4, which gives ABMD stock a 52-week price range ratio of 75.12%
ABIOMED Inc. currently has a PE ratio of 75.10, a price-to-book (PB) ratio of 11.82, a price-to-sale (PS) ratio of 24.85, a price to cashflow ratio of 54.70, a PEG ratio of 2.32, a ROA of 14.68%, a ROC of 17.37% and a ROE of 16.70%. The company’s profit margin is 27.82%, its EBITDA margin is 30.50%, and its revenue ttm is $606.28 Million , which makes it $13.40 revenue per share.
Of the last four earnings reports from ABIOMED Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.10 for the next earnings report. ABIOMED Inc.’s next earnings report date is 29th Apr 2021.
The consensus rating of Wall Street analysts for ABIOMED Inc. is Moderate Buy (2.19), with a target price of $378, which is +14.61% compared to the current price. The earnings rating for ABIOMED Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ABIOMED Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ABIOMED Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.81, ATR14 : 15.31, CCI20 : 138.17, Chaikin Money Flow : 0.19, MACD : -5.18, Money Flow Index : 72.17, ROC : 13.22, RSI : 39.05, STOCH (14,3) : 96.08, STOCH RSI : 0.39, UO : 64.57, Williams %R : -3.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ABIOMED Inc. in the last 12-months were: Andrew J. Greenfield (Option Excercise at a value of $662 500), Andrew J. Greenfield (Sold 34 312 shares of value $11 104 551 ), Dorothy E. Puhy (Sold 35 000 shares of value $9 622 347 ), Martin P. Sutter (Option Excercise at a value of $239 760), Martin P. Sutter (Sold 37 500 shares of value $8 494 765 ), Paul G. Thomas (Sold 4 000 shares of value $1 213 640 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.